Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Hagens Berman Advisory Resource Group Makes New $946,000 Investment in AstraZeneca PLC

December 13, 2024
AstraZeneca PLC (NASDAQ:AZN) has recently received a significant investment from Hagens Berman Advisory Resource Group in the amount of $946,000. This new investment highlights the confidence that the advisory group has in the long-term potential of AstraZeneca as a value stock.

With 86% ownership of the shares, AstraZeneca PLC (LON:AZN) is heavily dominated by institutional investors. This not only reflects the trust that institutional investors have in the company but also indicates the stability and growth prospects it offers.

AstraZeneca's commitment to innovation and research has led to several breakthroughs in pharmaceuticals, making it a key player in the healthcare industry. This investment from Hagens Berman Advisory Resource Group further supports the company's mission to develop life-saving medications and improve patient outcomes.

While recent reports of a probe by the PRC have caused a temporary decrease in AstraZeneca's share price, the company remains resilient. The alleged fraud and corruption claims should not overshadow the overall positive outlook for AstraZeneca.

Investors looking for a long-term value stock should consider AstraZeneca. With its strong institutional ownership and commitment to innovation, the company is well-positioned for future growth. Consultation with professionals from Stocks Prognosis is recommended for accurate forecasts on the movement of AstraZeneca's shares.
If you want to leave a comment, then you need Login or Register





Other data for AZN

Related data

AZNJune 26, 2025AstraZeneca's New Phase I Study on AZD5492: What Investors Need to Know  ~1 min.

AstraZeneca PLC has recently announced positive results from a Phase I study on its new drug candidate, AZD5492....


AZNMarch 20, 2025AstraZeneca AZN: Among the Best Diabetes Stocks to Buy According to Billionaires  ~1 min.

AstraZeneca PLC (AZN) has been recognized as one of the best diabetes stocks to buy by billionaires....


AZNMarch 16, 2025AstraZeneca's Experimental Blood Pressure Drug Could Become a Blockbuster  ~2 min.

AstraZeneca PLC (NASDAQ:AZN) has recently developed an experimental drug for treating high blood pressure, which experts believe has a strong potential to become a blockbuster in the pharmaceutical market....


AZNMarch 15, 2025AstraZeneca's Experimental Blood Pressure Drug Shows Promising Results, Outperforms Broader Market  ~1 min.

AstraZeneca PLC's recent experimental blood pressure drug has shown promising results, performing significantly better than the broader market....


AZNMarch 14, 2025AstraZeneca's Imfinzi success a step towards revolutionizing cancer treatment  ~2 min.

AstraZeneca PLC (AZN) continues to make significant strides in the field of cancer treatment with its groundbreaking drug, Imfinzi....


AZNMarch 5, 2025ASTRAZENECA PLC Stock Hits Price Target Forecast with 13.63% Profit  ~1 min.

On January 28, 2025, QuantWave issued a long signal for ASTRAZENECA PLC stock when it was trading at 68.61 $....


AZNMarch 4, 2025ASTRAZENECA PLC Hits Price Target Forecast with 13.62% Profit: A Sign of QuantWave's Accuracy  ~2 min.

ASTRAZENECA PLC (AZN) recently reached the price target forecast set by QuantWave on March 4, 2025, resulting in a profit of 13.62% for investors who followed the long signal issued on February 4, 2025....


AZNFebruary 28, 2025AstraZeneca PLC AZN: A Global Pharmaceutical Giant with Promising Growth Potential  ~2 min.

AstraZeneca PLC (AZN) is a renowned multinational pharmaceutical company with a strong presence in the global market....


AZNFebruary 26, 2025AstraZeneca PLC's Groundbreaking Research Leads to Exciting Discoveries in the Field of Medicine  ~2 min.

AstraZeneca PLC, a leading pharmaceutical company, has made significant advancements in the field of medicine through its groundbreaking research....


AZNFebruary 24, 2025AstraZeneca PLC Announces Positive Results from Clinical Trial  ~2 min.

AstraZeneca PLC, a leading pharmaceutical company, announced today that its latest clinical trial for a new drug has yielded positive results....


AstraZeneca PLC (AZN): A Rising Star in the Pharmaceutical Industry  ~2 min.

AstraZeneca PLC (AZN) has been recognized as one of the best diabetes stocks to buy by billionaires....


AZNMarch 16, 2025AstraZeneca's Experimental Blood Pressure Drug Could Become a Blockbuster  ~2 min.

AstraZeneca PLC (NASDAQ:AZN) has recently developed an experimental drug for treating high blood pressure, which experts believe has a strong potential to become a blockbuster in the pharmaceutical market....


AZNDecember 10, 2024AstraZeneca PLC: A Leading Pharmaceutical Company with Strong Momentum  ~2 min.

AstraZeneca PLC (AZN) is a renowned pharmaceutical company that has been experiencing strong momentum in the market....


AZNDecember 7, 2024Why AstraZeneca PLC AZN is Revolutionizing the Pharmaceutical Industry  ~2 min.

AstraZeneca PLC AZN, a leading multinational pharmaceutical company, is making groundbreaking strides in the industry....


AZNDecember 1, 2024Why AstraZeneca PLC AZN is Gaining Momentum in the Pharmaceutical Industry  ~2 min.

AstraZeneca PLC (AZN) has been making headlines in the pharmaceutical industry due to its promising prospects and investment potential....